Spots Global Cancer Trial Database for Hepassocin Levels in Patients With Polycystic Ovary Syndrome
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Hepassocin Levels in Patients With Polycystic Ovary Syndrome
Official Title: Hepassocin Levels in Patients With Polycystic Ovary Syndrome
Study ID: NCT04369248
Interventions
Study Description
Brief Summary: The investigators aimed to investigate hepassocin levels in patients with polycystic ovary syndrome (PCOS). There are 3 groups aged between 18 and 35 years as non-obese healthy women, non-obese women with PCOS, and obese women (BMI\>30) with PCOS.
Detailed Description: Hepassocin, also known as Fibrinogen-like-protein or hepatocyte-derived fibrinogen-related protein 1, is a new marker for obesity and insulin resistance. In hepatic injury, it protects liver cells and promotes regeneration. High levels of hepassocin was shown to be independently associated with HOMA-IR and diabetes. Since insulin resistance is known to be seen in patients with PCOS, it may be expected that hepassocin levels may be higher in this group of patients.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: FEMALE
Healthy Volunteers: Yes
Locations
Gaziosmanpasa Taksim Education and Research Hospital, Istanbul, , Turkey
Contact Details
Name: fatma ketenci gencer
Affiliation: Gaziosmanpasa Taksim Education and Research Hospital
Role: STUDY_DIRECTOR
Name: sibel bektas
Affiliation: Gaziosmanpasa Taksim Education and Research Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
